NEW YORK (GenomeWeb News) — Tm Bioscience today said it has amended its licensing agreement with Sirius Genomics to defer a $2 million payment that was due Sept. 5 until sometime in October 2007, or “90 days after completion of certain milestones by Sirius.”
Tm Bioscience’s patented materials include an FDA approved genotyping test for cystic fibrosis, as well as other tests based on the company’s Tag-it Universal Array platform.
Sirius works to identify biological pathways that may help to improve study design and assist in the selection of candidates for clinical trials.
The agreement deals with diagnosis concerning protein C and arginine vasopressin.